Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Lynch

Showing results (111-120 of 251) with videos related to

Pageof 26
Sort By:
Neurology and Therapy|April 30, 2025
Safety Monitoring of Omaveloxolone in Friedreich Ataxia: Results from One Year of Clinical TreatmentKatherine Gunther, Victoria Profeta, Medina Keita, et al.
Expert Review of Neurotherapeutics|July 21, 2017
Pharmacological therapeutics in Friedreich ataxia: the present stateCassandra Strawser, Kimberly Schadt, Lauren Hauser, et al.
Molecular Therapy. Nucleic Acids|July 24, 2025
Antisense oligonucleotide therapy for patients with Friedreich's ataxia carrying the c.165+5G>C splicing mutationPouiré Yameogo, Selina Aguilar, Thazha P Prakash, et al.
BMC Biotechnology|June 28, 2018
Membrane-bound and soluble forms of an NMDA receptor extracellular domain retain epitopes targeted in auto-immune encephalitisRashmi Sharma, Fetweh H Al-Saleem, Rama Devudu Puligedda, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 2, 2008
Urinary isoprostanes in Friedreich ataxia: lack of correlation with disease featuresLauren M Myers, David R Lynch, Jennifer M Farmer, et al.
Archives of Biochemistry and Biophysics|December 1, 2020
Mitochondrial dysfunction in the development and progression of neurodegenerative diseasesJoseph Johnson, Elizabeth Mercado-Ayon, Yesica Mercado-Ayon, et al.
Communications Medicine|October 29, 2024
At-home wearable-based monitoring predicts clinical measures and biological biomarkers of disease severity in Friedreich's AtaxiaRam Kinker Mishra, Adonay S Nunes, Ana Enriquez, et al.
Journal of Neurology|December 8, 2023
Frataxin analysis using triple quadrupole mass spectrometry: application to a large heterogeneous clinical cohortDavid R Lynch, Teerapat Rojsajjakul, S H Subramony, et al.
Muscle & Nerve|May 8, 2002
Near infrared muscle spectroscopy in patients with Friedreich's ataxiaDavid R Lynch, Gwen Lech, Jennifer M Farmer, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|December 16, 2003
Selective activation induced cleavage of the NR2B subunit by calpainKelly L Simpkins, Rodney P Guttmann, Yina Dong, et al.
Pageof 26

Showing results (111-120 of 251) with videos related to

Sort By:
Pageof 26
Neurology and Therapy|April 30, 2025
Safety Monitoring of Omaveloxolone in Friedreich Ataxia: Results from One Year of Clinical TreatmentKatherine Gunther, Victoria Profeta, Medina Keita, et al.
Expert Review of Neurotherapeutics|July 21, 2017
Pharmacological therapeutics in Friedreich ataxia: the present stateCassandra Strawser, Kimberly Schadt, Lauren Hauser, et al.
Molecular Therapy. Nucleic Acids|July 24, 2025
Antisense oligonucleotide therapy for patients with Friedreich's ataxia carrying the c.165+5G>C splicing mutationPouiré Yameogo, Selina Aguilar, Thazha P Prakash, et al.
BMC Biotechnology|June 28, 2018
Membrane-bound and soluble forms of an NMDA receptor extracellular domain retain epitopes targeted in auto-immune encephalitisRashmi Sharma, Fetweh H Al-Saleem, Rama Devudu Puligedda, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 2, 2008
Urinary isoprostanes in Friedreich ataxia: lack of correlation with disease featuresLauren M Myers, David R Lynch, Jennifer M Farmer, et al.
Archives of Biochemistry and Biophysics|December 1, 2020
Mitochondrial dysfunction in the development and progression of neurodegenerative diseasesJoseph Johnson, Elizabeth Mercado-Ayon, Yesica Mercado-Ayon, et al.
Communications Medicine|October 29, 2024
At-home wearable-based monitoring predicts clinical measures and biological biomarkers of disease severity in Friedreich's AtaxiaRam Kinker Mishra, Adonay S Nunes, Ana Enriquez, et al.
Journal of Neurology|December 8, 2023
Frataxin analysis using triple quadrupole mass spectrometry: application to a large heterogeneous clinical cohortDavid R Lynch, Teerapat Rojsajjakul, S H Subramony, et al.
Muscle & Nerve|May 8, 2002
Near infrared muscle spectroscopy in patients with Friedreich's ataxiaDavid R Lynch, Gwen Lech, Jennifer M Farmer, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|December 16, 2003
Selective activation induced cleavage of the NR2B subunit by calpainKelly L Simpkins, Rodney P Guttmann, Yina Dong, et al.
Pageof 26